Amgen's D-mab beats Fosamax in trial
This is a discussion on Amgen's D-mab beats Fosamax in trial within the Biotechnology News forum, part of the Industry News and Updates category; In a head-to-head trial, Amgen's twice-yearly osteoporosis drug denosumab outperformed weekly oral doses of Merck's...
|
|||||||
| Register | Help | Members List | Mark Forums Read |
05-28-2008, 04:34 PM
|
|||
|
|||
Amgen's D-mab beats Fosamax in trial
In a head-to-head trial, Amgen's twice-yearly osteoporosis drug denosumab outperformed weekly oral doses of Merck's
|
 |
«
Previous Thread
|
Next Thread
»
| Thread Tools | |
| Display Modes | |
Linear Mode
|
|
|
||||
| Thread | Thread Starter | Forum | Replies | Last Post |
| FDA approves first generic versions of Fosamax | industry_news | FDA News | 0 | 02-26-2008 03:30 PM |
© 2008 DrugManagementForum™ powered by |
 |